Zhang is responsible for identifying early stage targets, small molecules and monoclonal antibodies for our drug discovery group and the licensing of mature programmes to industry, particularly in China.
Zhi Zhang
Latest news
-
LifeArc and Cleveland Clinic join forces to develop new monoclonal antibody therapeutics for patients with high unmet medical needs
-
Third global Longitude Prize to be launched in 2025 focusing on ALS
-
LifeArc appoints Chief Medical Officer to deliver more scientific breakthroughs for patients